A Phase 2 interventional study of Vosoritide Injection in Noonan Syndrome, sponsored by BioMarin Pharmaceutical. Terminated at 38 sites in 7 countries. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment
BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibility and the current treatment landscape for children with Noonan syndrome. This decision is not related to the safety or efficacy of vosoritide
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Noonan Syndrome with a site in United States — 6 open to participants now, 9 under way, 3 of them phase 3. Noonan Syndrome · United States.
Among the 20 studies in Noonan Syndrome with a site in United States, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 2, and was the 18th registered.
49 studies on the registry are indexed under Noonan Syndrome; 21 are open to participants now.
Browse Noonan Syndrome studies →6 of the 20 studies in Noonan Syndrome with a site in United States are open now. Recruiting first, the newest first:
Ascendis Pharma A/S · Sites in United States, France, Germany and 4 more countries
Ages 2–17
National Cancer Institute (NCI) · Sites in United States
Ages 18+ · Healthy volunteers
National Cancer Institute (NCI) · Sites in United States
Ages 1 mo–99 yrs · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Noonan Syndrome studies recruiting now, 10 (63%) set no upper age limit and 4 (25%) stop at 75 or younger; 13 take children under 18; 7 take healthy volunteers.
This study: 3 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 3
First in 2012; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 18 is below the median of 52 across 32 interventional studies indexed under Noonan Syndrome.
Median enrollment 56 across the 17 interventional studies, 1,000 across the 3 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 20 have an industry lead sponsor. The 10 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
BioMarin Pharmaceutical has 1 study filed under Noonan Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Noonan Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05361811National Cancer Institute (NCI)Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Noonan Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study in children with Noonan syndrome is to evaluate the effect of 3 doses of vosoritide on growth as measured by AGV after 6 months of treatment. The long-term efficacy and safety of vosoritide at the therapeutic dose will be evaluated up to FAH.
This is a Phase 2, randomized, multicenter, study of vosoritide in children with Noonan syndrome who have inadequate growth during or after human growth hormone (hGH) treatment. The study is intended to characterize the short-term efficacy and safety of 3 dosing regimens of vosoritide. The efficacy and safety of the vosoritide therapeutic dose will be further evaluated, and an analysis of the impact of vosoritide on final adult height (FAH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Vosoritide - Dose 1 Injection • Experimental Drug Lyophilized powder for reconstitution
Drug: Vosoritide Injection
Drug: Vosoritide - Dose 2 Injection • Experimental Drug Lyophilized powder for reconstitution
Drug: Vosoritide Injection
Drug: Vosoritide Dose 3 Injection • Experimental Drug Lyophilized powder for reconstitution
Drug: Vosoritide Injection
Modified recombinant human C-type natriuretic peptide Vosoritide
Change from baseline in Annualized Growth Velocity (AGV)
Time frame: At 6 months
Incidence of treatment-emergent adverse events
Time frame: Until the end of the study, up to 15 years
Incidence of new diagnosis of hypertrophic cardiomyopathy in children with Noonan syndrome
Time frame: Every 12 months through the end of the study, up to 15 years
Incidence of cardiac conditions requiring discontinuation of study treatment
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in height
Time frame: Every 6 months through the end of the study, up to 15 years
Change from baseline in height Z-score
Time frame: Every 6 months through the end of the study, up to 15 years
Change from baseline in 12-month interval AGV
Time frame: Until the end of the study, up to 15 years
Change from baseline in upper to lower body segment ratio
Time frame: Until the end of the study, up to 15 years
Change from baseline in arm span to height ratio
Time frame: Until the end of the study, up to 15 years
Change from baseline in height up to Final Adult Height (FAH)
Time frame: Every 6 months through the end of the study, up to 15 years
Change from baseline in height Z-score up to FAH
Time frame: Every 6 months through the end of the study, up to 15 years
12-month interval AGV summarized by age and sex up to FAH
Time frame: Every 12 months through the end of the study, up to 15 years
Tanner stage over the course of the study
Time frame: Every 6 months through the end of the study, up to 15 years
Time vosoritide is present at maximum concentration (Tmax)
Time frame: Every 6 months through the end of the study, up to 15 years
Maximum vosoritide observed plasma concentration (Cmax)
Time frame: Every 6 months through he end of the study, up to15 years
Area under the plasma vosoritide concentration time-curve from time 0 to the last measurable concentration (AUC0-t)
Time frame: Every 6 months through the end of the study, up to 15 years
Area under the plasma vosoritide concentration time-curve from time 0 to infinity (AUC0-∞)
Time frame: Every 6 months through the end of the study, up to 15 years
Elimination half-life of vosoritide (t½)
Time frame: Every 6 months through the end of the study, up to 15 years
Apparent clearance of vosoritide (CL/F)
Time frame: Every 6 months through the end of the study, up to 15 years
Apparent volume of distribution of vosoritide (Vz/F)
Time frame: Every 6 months through the end of the study, up to 15 years
Change from pre-dose in urine cyclic guanine monophosphate (cGMP)
Time frame: Every 6 months through the end of the study, up to 15 years
Change from baseline in serum collagen X marker (CXM)
Time frame: Every 6 months through the end of the study, up to 15 years
Change from baseline in bone age/chronological age
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in total body (less head) BMD Z-score
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in lumbar spine bone mineral density (BMD) Z-score
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in total body (less head) bone mineral content (BMC)
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in lumbar spine BMC. Change from baseline in lower extremity BMD/BMC [Time Frame: Every 12 months through the end of the study, up to 15 years].
Time frame: Every 12 months through the end of the study, up to 15 years
Change in the growth plates, long bone growth and bone morphology based on whole length lower extremity X-rays [Time Frame: Every 12 months through the end of the study, up to 15 years]
Time frame: Every 6 months through the end of the study, up to 15 years
Incidence of bone-related events of special interest (fracture, slipped capital femoral epiphysis and avascular necrosis or osteonecrosis)
Time frame: Throughout study
Change from baseline in the physical domain score and total score of the QoLISSY
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in the physical and social domain scores and total score of the PedsQL
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in PGI-S and CaGI-S item scores
Time frame: Every 12 months through the end of the study, up to 15 years
PGI-C and CaGI-C item scores
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in PROMIS-SF Physical Activity score
Time frame: Every 12 months through the end of the study, up to 15 years
Change from baseline in KABC-II NVI scores
Time frame: Every 12 months through the end of the study, up to 15 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Sep 2026, 21 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Mar 2027 → Sep 2026 and completion Sep 2041 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibility and the current treatment landscape for children with Noonan syndrome. This decision is not related to the safety or efficacy of vosoritide
BioMarin has decided to discontinue the study after assessing a number of factors, including study feasibility and the current treatment landscape for children with Noonan syndrome. This decision is not related to the safety or efficacy of vosoritide
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vosoritide